Skip to main content
Caplight Logo









PL BioScience

PL BioScience

Private
AachenHealthcare & Life Scienceshttps://pl-bioscience.com/

Last Round

Series A

Aug 12, 2024

Total Funding Raised

$13.06M

Company Overview

PL BioScience is a biotechnology company that develops and manufactures animal-free cell culture media, specifically Human Platelet Lysate (HPL), for use in regenerative medicine, cell therapy, and biopharmaceutical research.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Biotech Equipment

Business Model

B2B

Customer Profile

Hardware Sales, Services & Consulting

AI Layer

Non-AI

Keywords

hPLhuman platelet lysatecell culture supplementcell culture mediaanimal-free mediaregenerative medicinecell therapyxeno-free mediafetal bovine serum alternativeFBS alternativeGMP-grade reagentsbioprocessingcell expansionbiotechnology manufacturing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

PL BioScience Comparables

Compare PL BioScience with similar companies based on industry and business-model similarity.

PL BioScience comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Mill Creek Life Sciences
87%
AventaCell BioMedical Corp.
86%
Compass Biomedical
84%

PL BioScience Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AAug 12, 2024
SeedMay 21, 2021

Key People

Founding team and executive leadership

Hatim Hemeda

CEO Founder

Founding Team

Oliver Dick

CTO

Executive Team

PL BioScience Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Feb 20, 2026

    Exclusive agreement with Summit Pharmaceuticals International Corporation for the Japanese market.

  • Dec 22, 2025

    Added Iwai Chem, a chemicals/life sciences distributor, as a customer.

Recent news

Latest coverage and updates

  • hiresJun 17, 2026

    PL BioScience GmbH hires Maik W. Jornitz as Board of Directors.

PL BioScience Filings

Explore SEC and related filing metadata, where available.

PL BioScience filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about PL BioScience's valuation, stock price, and market status.

Is PL BioScience a public or private company?

PL BioScience is a private company.

What is the current stock price of PL BioScience?

PL BioScience is a private company with no public stock price. No recent secondary market data is available.

How much is PL BioScience worth (valuation)?

Valuation information for PL BioScience is not publicly available.

Can I buy PL BioScience stock?

PL BioScience shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was PL BioScience's last funding round?

PL BioScience's most recent funding round was Series A on August 8, 2024.

Who are the main investors in PL BioScience?

Key investors in PL BioScience include Better Ventures, b.value AG, AVANT BIO.

Will PL BioScience IPO soon?

No public IPO plans have been announced for PL BioScience.

How can I track PL BioScience secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor PL BioScience's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersAachen
Employee Range28
Year Founded2015
Last FundingAug 12, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?